@arpitrage@ipeirotis Pangram 4’s false positive rate in general *as of Aug 31, 2026* is low. This will certainly lead to an arms race with an ever shrinking delta in which the detectors and evaders move. I am not at all certain that any given version of pangram will stay strictly dominant > a year.
@mike64_t You’re clearly right. I mean look at the justification for the “tell” in this instance. People don’t recognize excesses when it’s their side engaging in it.
@SandroAmbuehl Attitudes towards the young correlate really well with age.
35 - 65: Kids these days have terrible judgement.
65+: Kids will be alright.
Coincidentally, only one of those brackets has to defend and justify its position against newcomers.
@nalidoust I mean critics were clearly right?? Take Covid out and it’s very dubious Moderna would be still around + that phase 3 press release is a testament to their clinical trials team, not their IP or science
@iskander I suspect Moderna & Merck put their A team on this (clinical trials, not product dev) and that’s the discrepancy. I have a couple ideas what may have turned the dial in their favor on the phase 2 study and am eagerly awaiting more info on this phase 3 study
@Richard_She Lots of similarities to the human genome project. Grand claims, ample funding and lots of hope. We’re much better equipped now thanks to the hgp, but ultimately it simply became another tool/resource we rely on, rather than an end. I think there are lots of parallels
@LocasaleLab This sounds a little hyperbolic. This framework IMO has either a too low estimation of the grad student or a too high estimation of the LLM. Further, I can’t think of a single example where $20 would be insufficient but $100 would be enough. Either they both are or neither is…
@andrewho03 It's Anthropic's game to lose now... and they certainly have meaningful structural disadvantages. They'd better hope advances gained from high quality data will beat compute abundance